TrumpRx pricing website analysis

Pharma ads, biotech IPOs, $1M longevity programs, oh my!

This month's Digital Health Download skews towards biotech, which is having a moment. Tune in to hear Halle and Michael cover the latest headlines.

We cover:

• Why pharma ads are surging and the growing push for restrictions on D2C drug advertising
• Hims & Hers’ $1.15B acquisition of Eucalyptus, its global expansion strategy, and the FDA crackdown on compounded GLP‑1 drugs
• The return of biotech IPOs, with Eikon Therapeutics and Generate Biomedicines signaling investor interest in platform‑based drug discovery
• Vaccine makers scaling back research amid policy uncertainty, declining uptake, and tighter funding
• TrumpRx’s “most favored nation” drug pricing approach, and what one STAT analysis found
• Bryan Johnson’s $1M per year “Immortals” longevity program

—

Show notes:

• Should drug companies be advertising to consumers? (The New York Times) 
• Hims & Hers Enters $1.15 Billion Agreement to Acquire Eucalyptus (PharmExec.com)
• A sign biotech is back? Four drugmakers go public, raising nearly $1 billion in all (STAT)
• Vaccine Makers Curtail Research and Cut Jobs (The New York Times) 
• TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics (STAT)
• Bryan Johnson's Immortals: $1M to try longevity regimen (Axios) 

—

"Halle Tecco wanted to see tech used for better medical services and getting people engaged in their own health. Now, she’s written a book on how she went about it." - The WSJ

Massively Better Healthcare is out now!

—

Rock Health's annual CEO Summit is returning to the New York Stock Exchange on March 27th! Learn more and nominate a CEO to join this invite-only event here.

—

📍 Connect with us:

Heart of Healthcare website

LinkedIn

Instagram

Youtube

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.